利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.037 秒)

    Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood
    3.
    发明申请
    Food for improving clinical conditions capable of lowering the concentration of low-molecular weight nitrogen-containing compounds in blood 审中-公开
    用于改善能够降低血液中低分子量含氮化合物浓度的临床条件的食物

    公开(公告)号：US20060210606A1

    公开(公告)日：2006-09-21

    申请号：US10549914

    申请日：2004-03-26

    申请人： Yasumi Yugari ,  Takaaki Kobayashi ,  Shu Furuya

    发明人： Yasumi Yugari ,  Takaaki Kobayashi ,  Shu Furuya

    IPC分类号： A61K47/00 ,  A61K31/715

    CPC分类号： A61K31/715 ,  A23L33/21

    摘要： The present invention aims at preventing or retarding a transition to hemodialysis treatment in kidney failure or decreasing the number of implementation of the hemodialysis therapy and preventing or lessening occurrence of accompanying hyperammonemia in hepatic insufficiency. To accomplish the purposes described above, the pathological improvement food of the invention is featured by being composed chiefly of indigestible polysaccharides and having restricted addition of protein components. Energy produced by exploiting the indigestible polysaccharides contributes to fungal protein synthesis using, as a N-source, urea or ammonia secretion into the intestine and excretion of proliferated bacteria with feces, so that nitrogen-containing low-molecular substances in the blood can be decreased, thereby to improve disorder of the kidney and liver.

    摘要翻译： 本发明旨在防止或延缓肾衰竭期间对血液透析治疗的过渡，或减少血液透析治疗的实施次数，并预防或减轻伴随的高血氨酸在肝功能不全中的发生。 为了实现上述目的，本发明的病理改善食品的特征在于主要由难消化的多糖组成并且限制蛋白质组分的添加。 通过开发不消化的多糖产生的能量有助于使用尿素或氨分泌到肠中并用粪便排泄增殖细菌作为N源的真菌蛋白质合成，使得血液中的含氮低分子物质可以减少 ，从而改善肾脏和肝脏的紊乱。

    Amino acid derivatives, methods of preparing said derivatives and antihypertensive drugs containing them
    6.
    发明授权
    Amino acid derivatives, methods of preparing said derivatives and antihypertensive drugs containing them 失效
    氨基酸衍生物，制备所述衍生物的方法和含有它们的抗高血压药物

    公开(公告)号：US4472381A

    公开(公告)日：1984-09-18

    申请号：US458844

    申请日：1983-01-18

    申请人： Shumpei Sakakibara ,  Yasumi Yugari ,  Shigebumi Hashimoto

    发明人： Shumpei Sakakibara ,  Yasumi Yugari ,  Shigebumi Hashimoto

    IPC分类号： A61K38/00 ,  C07K5/08 ,  A61K37/00 ,  C07C103/52

    CPC分类号： C07K5/0827 ,  A61K38/00 ,  Y10S530/80

    摘要： The present invention relates to an amino acid derivative represented by the formula ##STR1## wherein R.sub.1 and R.sub.2 represent hydroxyl, alkyloxy, aryloxy, arylkyloxy, alkyl, aryl, or aralkyl; R.sub.3, R.sub.5, R.sub.8 and R.sub.11 are hydrogen or alkyl; R.sub.4, R.sub.7 and R.sub.10 are hydrogen, or substituted or unsubstituted alkyl, aryl or aralkyl; R.sub.6 and R.sub.9 are hydrogen, alkyl, aryl, or aralkyl; R.sub.12 is hydroxyl, alkyloxy, aryloxy, aralkyloxy, amino, mono- or di-alkyl-, aryl- or aralkyl amino; and R.sub.6 and R.sub.7 combined together, and R.sub.9 and R.sub.10 combined together independently may form a substituted or unsubstituted alkylene bridge. The present invention also relates to a method of preparing said amino acid derivatives, and to anti-hypertensive drugs containing them.

    摘要翻译： 本发明涉及由下式表示的氨基酸衍生物：其中R1和R2表示羟基，烷氧基，芳氧基，芳基氧基，烷基，芳基或芳烷基; R3，R5，R8和R11是氢或烷基; R 4，R 7和R 10是氢或取代或未取代的烷基，芳基或芳烷基; R6和R9是氢，烷基，芳基或芳烷基; R 12是羟基，烷氧基，芳氧基，芳烷氧基，氨基，单 - 或二 - 烷基 - ，芳基 - 或芳烷基氨基; 并且R6和R7组合在一起，并且独立地结合在一起的R 9和R 10可以形成取代或未取代的亚烷基桥。 本发明还涉及制备所述氨基酸衍生物的方法和含有它们的抗高血压药物。

    PERITONEAL DIALYSATE
    7.
    发明申请
    PERITONEAL DIALYSATE 审中-公开
    皮肤透析

    公开(公告)号：US20100187476A1

    公开(公告)日：2010-07-29

    申请号：US12733163

    申请日：2007-08-15

    申请人： Yasumi Yugari ,  Tsutomu Sanaka

    发明人： Yasumi Yugari ,  Tsutomu Sanaka

    IPC分类号： C09K3/00

    CPC分类号： A61M1/287 ,  A61K31/185 ,  A61K31/7016 ,  A61K45/06 ,  A61K2300/00

    摘要： This invention provides a safe and highly stable peritoneal dialysate, which causes neither peritoneal membrane disorders nor peritoneal sclerosis associated with frequently repeated peritoneal dialysis treatment, which can protect residual renal functions in chronic renal failure, which inhibits the progress of renal damage over a long period of time, and which enables peritoneal dialysis treatment of diabetic patients. This peritoneal dialysate contains 0.05 to 3.5 w/v % of taurine and 0.1 to 6.5 w/v % of trehalose as osmotic agents and has a pH value adjusted between 6.5-7.5.

    摘要翻译： 本发明提供了一种安全和高度稳定的腹膜透析液，其既不引起腹膜膜病变，也不引起与经常重复腹膜透析治疗相关的腹膜硬化症，其可以保护慢性肾功能衰竭中的残留肾功能，其长期抑制肾损伤的进展 的时间，并且其能够进行糖尿病患者的腹膜透析治疗。 该腹膜透析液含有0.05〜3.5w / v％的牛磺酸和0.1〜6.5w / v％的海藻糖作为渗透剂，pH值调节在6.5〜7.5之间。